FDA WARNING_LETTER - Meds India LTD

The FDA issued a Warning Letter after reviewing numerous websites offering unapproved new drugs and misbranded drugs for sale, violating sections 301(a), 301(d), 502(f), 503(b), and 505(a) of the FD&C Act.

The violations include selling unapproved new drugs like "Generic Nolvadex" (for breast cancer) and "Generic Meridia" (for obesity). "Generic Nolvadex" lacks an FDA-approved application and the required black box warning for serious adverse events, unlike its approved counterparts. "Generic Meridia" is an unapproved new drug, as the brand-name Meridia was withdrawn from the U.S. market in 2010 due to increased risks of heart attack and stroke.

Additionally, the websites offer misbranded prescription drugs such as "Generic Valium" and "Generic Xanax" without requiring a prescription, despite being controlled substances with abuse potential and requiring licensed practitioner supervision. These products also lack adequate directions for use. Unapproved Accutane (isotretinoin) is also sold, which was withdrawn from the market in 2010. Furthermore, isotretinoin products are misbranded as they bypass the FDA's restricted distribution REMS program (iPLEDGE), which is crucial for preventing fetal exposure and informing users of serious risks.

The FDA requires immediate cessation of marketing these viol